// App-Quantinova.ai

TPS5073 : Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy: PREMIERE-SOGUG Trial.

Researchers

Presenter

  • Enrique Grande

Principal Investigators

  • Enrique Gonzalez-Billalabeitia

  • Ignacio Duran

  • M Isabel Sez

  • Begona Mellado

  • Mara Jose Mendez-Vidal

  • Sergio Vazquez-Estevez

  • Ovidio Fernandez Calvo

  • Maria Piedad Fernandez Perez

  • Teresa Alonso

  • Aranzazu Gonzalez del Alba

  • Javier Puente

  • Angel Rodriguez Sanchez

  • Albert Font

  • Miguel Angel Climent

  • Luis Leon Mateos

Medical Centers

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • H. Universitario Miguel Servet, Zaragoza, Spain

  • Hospital Universitario Morales Meseguer, Murcia, Spain

  • Complejo Hospitalario De Pontevedra, Pontevedra, Spain

  • Hospital Clinico Universitario San Carlos, Madrid, Spain

  • Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain

  • Hospital Universitario Lucus Augusti, Lugo, Spain

  • Parc Tauli Sabadell Hospital Universitari, Sabadell, Spain

  • Hospital Universitario Son Espases, Palma de Mallorca, Spain

  • Hospital Universitario 12 de Octubre, Madrid, SpainHospital of Leon, Leon, SpainMedical Oncology Department, Institut Catala dOncologia, Hospital Germans Trias i Pujol, Badalona, Spain

  • Hospital Virgen de la Victoria, Malaga, Spain

  • Hospital Universitario Reina Sofia, Cordoba, Spain

  • Translational Genomics and Targeted Therapeutics in Oncology.IDIBAPS. Medical Oncology Department. Hospital Clinic, Barcelona, Spain

  • Complexo Universitario de Ourense, Ourense, Spain

  • Ramon y Cajal University Hospital, Madrid, Spain

  • Instiuto Valenciano de Oncologia, Valencia, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Metastatic castration-resistant prostate cancer

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02288936

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved